{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:37:32Z","timestamp":1790264252471,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T00:00:00Z","timestamp":1178582400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Most studies have found no increased risk of colon cancer associated with hormone replacement therapy (HRT), or even a decreased risk. But information about the effects of different HRT preparations is lacking.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A case-control study was performed within Germany in collaboration with regional cancer registries and tumor centers. Up to 5 controls were matched to each case of colon cancer. Conditional logistic regression analysis was applied to estimate crude and adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Stratified analyses were performed to get an impression of the risk associated with different estrogens and progestins.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 354 cases of colon cancer were compared with 1422 matched controls. The adjusted overall risk estimate for colon cancer (ColC) associated with ever-use of HRT was 0.97 (0.71 \u2013 1.32). No clinically relevant trends for ColC risk were observed with increasing duration of HRT use, or increasing time since first or last HRT use in aggregate.<\/jats:p>\n            <jats:p>Whereas the overall risk estimates were stable, the numbers in many of the sub-analyses of HRT preparation groups (estrogens and progestins) were too small for conclusions. Nevertheless, if the ColC risk estimates are taken at face value, most seemed to be reduced compared with never-use of HRT, but did not vary much across HRT formulation subgroups. In particular, no substantial difference in ColC risk was observed between HRT-containing conjugated equine estrogens (CEE) or medroxyprogesterone acetate (MPA) and other formulations more common in Europe.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Ever-use of HRT was not associated with an increased risk of colon cancer. In contrary, most risk estimates pointed non-significantly toward a lower ColC risk in HRT ever user. They did not vary markedly among different HRT formulations (estrogens, progestins). However, the small numbers and the overlapping nature of the subgroups suggest cautious interpretation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-7-76","type":"journal-article","created":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T18:13:58Z","timestamp":1178648038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Colon cancer risk and different HRT formulations: a case-control study"],"prefix":"10.1186","volume":"7","author":[{"given":"J\u00fcrgen C","family":"Dinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar AJ","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"M\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Minh","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Assmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,5,8]]},"reference":[{"key":"726_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"Writing Group for the Women's Health Initiative Investigators","year":"2002","unstructured":"Writing Group for the Women's Health Initiative Investigators: Risks and benefit of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002, 288: 321-333. 10.1001\/jama.288.3.321.","journal-title":"JAMA"},{"key":"726_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00008469-199812000-00002","volume":"7","author":"S Franceschi","year":"1998","unstructured":"Franceschi S, La Vecchia C: Colorectal cancer and hormone replacement therapy: an unexpected finding. Eur J Cancer Prev. 1998, 7: 427-38. 10.1097\/00008469-199812000-00002.","journal-title":"Eur J Cancer Prev"},{"key":"726_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S0002-9343(99)00063-7","volume":"106","author":"F Grodstein","year":"1999","unstructured":"Grodstein F, Newcomb PA, Stampfer MJ: Postmenopausal hormone therapy and risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999, 106: 574-82. 10.1016\/S0002-9343(99)00063-7.","journal-title":"Am J Med"},{"key":"726_CR4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"The Women's Health Initiative Steering Committee","year":"2004","unstructured":"The Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004, 291: 1701-1712. 10.1001\/jama.291.14.1701.","journal-title":"JAMA"},{"key":"726_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jama.288.1.58","volume":"288","author":"S Hulley","year":"2002","unstructured":"Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D, HERS Research Group: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II). JAMA. 2002, 288: 58-66. 10.1001\/jama.288.1.58.","journal-title":"JAMA"},{"key":"726_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1472-6874-6-13","volume":"6","author":"JC Dinger","year":"2006","unstructured":"Dinger JC, Heinemann LAJ, M\u00f6hner S, Do Minh Thai , Assmann A: Breast cancer risk associated with different HRT formulations: A register-based case-control study. BMC Women's Health. 2006, 6: 13-10.1186\/1472-6874-6-13.","journal-title":"BMC Women's Health"},{"key":"726_CR7","volume-title":"Cancer incidence in five continents","author":"International Agency for Research on Cancer","year":"2002","unstructured":"International Agency for Research on Cancer: Cancer incidence in five continents. Edited by: Parkin DM, Whelan SLO, Ferlay J, Teppo L, Thomas DB. 2002, (WHO), IARC Scientific Publications No. 155, Lyon, VIII:"},{"key":"726_CR8","unstructured":"American Institute for Cancer Research: Food, nutrition and the prevention of cancer: a global perspective. Colon (p 216\u2013251). World Cancer Research Fund and American Institute of Cancer Research, Washington (USA) DC 20009 ISBN: 1 899533 05 2"},{"key":"726_CR9","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/humrep\/dei043","volume":"20","author":"M Dietel","year":"2005","unstructured":"Dietel M, Lewis MA, Shapiro S: Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Human Reproduction. 2005, 20: 2052-2060. 10.1093\/humrep\/dei043.","journal-title":"Human Reproduction"},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/ng0894-536","volume":"7","author":"JP Issa","year":"1994","unstructured":"Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB: Methylation of estrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994, 7: 536-40. 10.1038\/ng0894-536.","journal-title":"Nat Genet"},{"key":"726_CR11","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/S0378-5122(99)00065-1","volume":"33","author":"HP Schneider","year":"1999","unstructured":"Schneider HP: HRT and cancer risks: separating facts from fiction. Maturitas. 1999, 33: S65-S72. 10.1016\/S0378-5122(99)00065-1.","journal-title":"Maturitas"},{"key":"726_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/cmt.6.4.302.313","volume":"6","author":"S Shapiro","year":"2003","unstructured":"Shapiro S: Risk of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric. 2003, 6: 302-310.","journal-title":"Climacteric"},{"key":"726_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1385\/ENDO:24:3:203","volume":"24","author":"S Shapiro","year":"2004","unstructured":"Shapiro S: Adverse neoplastic and cardiovascular outcomes of HRT: the validity of the evidence. Endocrine. 2004, 24: 203-10. 10.1385\/ENDO:24:3:203.","journal-title":"Endocrine"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-7-76.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-7-76\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-7-76","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-7-76.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:50:06Z","timestamp":1630464606000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-7-76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,8]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-7-76","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,8]]},"assertion":[{"value":"7 December 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"76"}}